Financial results for FY2020 Q1 Financial Summary · 2020-05-20 · Financial results for FY2020 Q1 Financial Summary NIKKISO CO., LTD. May 15, 2020 Securities code: 6376 Disclaimer

Financial results for FY2020 Q1

Financial Summary

NIKKISO CO., LTD.May 15, 2020

Securities code: 6376

Disclaimer

This material contains forward-looking statements about future business performance. These statements by definition involve risks and uncertainties and are not intended to guarantee future performance. Actual results in the future may differ from the

estimates presented in the material herein due to changes in the business environment and other factors.

Copyright © 2020 NIKKISO CO., LTD. All rights reserved. 2

Ⅰ. Consolidated Performance

Appendix

Ⅱ. Performance by Business Segment

Ⅲ. Financial forecast

Company Information

Table of Contents

Ⅰ. Consolidated Performance


Both revenue and profit declined due to the spread of COVID-19, but the

Medical Division’s performance remained strong.

[Industrial]

In Industrial Business, shipments for existing oil-related business orders increased, but after-sales service

operations slowed down. Industrial gas/LNG-related business revenue rose as shipments for existing

orders increased. Last year’s sale of the particle analytical equipment business led to a revenue decrease

of 1.1 billion yen. Aerospace Business revenue from the sale of products for Boeing 737 MAX decreased.

[Medical]

In hemodialysis business, sales of machines remained on par with the previous year, but those of

disposables rose. The CRRT business has been strong due to higher needs for treatment of acute kidney

injury caused by COVID-19

Decreased by 998 million yen (Industrial: △2,195; Medical: +1,197)

Decreased by 886 million yen (Industrial: △836; Medical: +98)

Financial Summary

Revenue

Operating

Profit

[Industrial]

Both the Industrial Business and the Aerospace Business posted lower profit due to lower revenue.

[Medical]

Hemodialysis business profit declined slightly due to higher costs. CRRT business profit increased thanks to

improved profitability driven by revenue growth.


(Millions of JPY)

FY2019 Q1Jan.2019 – Mar.2019

FY2020 Q1Jan.2020 – Mar.2020

Change Change rate

Orders 43,657 40,079 △3,577 △8.2%

Revenue 37,480 36,481 △998 △2.7%

Operating profit 2,154 1,268 △886 △41.1%

Operating margin 5.7% 3.5%

Profit before tax 1,927 993 △933 △48.4%

Pretax profit margin 5.1% 2.7%

Profit for the yearattributable to owners of the company

1,402 733 △668 △47.7%

Profit marginattributable to owners of the company

3.7% 2.0%

Average foreign exchange rate

Against the US dollar (Yen) 110.22 108.86 △1.36 -

Against the euro (Yen) 125.16 120.08 △5.08 -

Consolidated Performance


Breakdown of Profit/Loss

(Millions of JPY)

FY2019Jan.2019 – Mar. 2019

FY2020Jan. 2020 – Mar. 2020

Change Remarks

Gross profit 12,849 11,343 △1,505

- Selling, general and administrative expenses 10,843 10,632 △210

- Other income 156 615 +459Income from a joint venture agreement in the deep UV-LED business (income from a licensing agreement: +500)

- Other expenses 7 58 +50

Operating profit 2,154 1,268 △886

- Financial income 39 83 ＋44

- Financial costs 336 359 ＋23

- Share of profit of associates and joint ventures accounted for using the equity method

70 0 △69

Profit before tax 1,927 993 △933

Closing rate

- Against the US dollar (Yen)

- Against the euro (Yen) 110.99 108.83 △2.16

Gross profit 124.56 119.55 △5.01

Ⅱ. Performance by Business Segment


Performance by Business Segment

(Millions of JPY)FY2019 Q1

Jan.2019 - Mar.2019

FY2020 Q1Jan.2020 - Mar.2020

YoY comparison

Change Change rate

Orders 43,657 40,079 △3,577 △8.2%

Industrial Business 28,588 25,064 △3,523 △12.3%

Industrial 24,423 21,210 △3,212 △13.2%

Aerospace 4,102 3,734 △367 △9.0%

Medical Business 15,068 15,014 △53 △0.4%

Revenue 37,480 36,481 △998 △2.7%

Industrial Business 24,304 22,108 △2,195 △9.0%

Industrial 20,055 18,329 △1,726 △8.6%

Aerospace 4,168 3,664 △504 △12.1%

Medical Business 13,175 14,372 +1,197 +9.1%

Operating ProfitOperating margin

2,1545.7%

1,2683.5%

△886 △41.1%

Industrial BusinessOperating margin

2,0898.6%

1,2535.7%

△836 △40.0%

Medical BusinessOperating margin

9006.8%

9987.0%

＋98 ＋10.9%

Corporate Expenses △835 △984 △148 -

* As part of the organizational restructuring implemented on January 1, 2020, the Precision Equipment Division was integrated into the Industrial Division. Therefore, figures for the Precision

Equipment Business are included in those of the Industrial Business. The particle analytical equipment business, a part of Precision Equipment Business, was sold in FY2019 Q3.


Orders Analysis (vs FY2019)

< Medical>< Aerospace >< Industrial, etc. >

FY2019 Q1(Jan.2019-Mar.2019)

Orders

43,657

＋111 △165

△2,599

△556△342

△24

Simpledecrease

(Millions of JPY)

Simpledecrease

Decreased 3,577 million yen year on year (Simple decrease: △2,830; Impact of FX: △747)

Simpleincrease

Impact of FX

Impact of FX Impact of FX

FY2020 Q1(Jan.2020-Mar.2020)

Orders

40,079

✓ LNG-related business: Orders

received declined due to the

postponement of investment

decisions or delays in project

completion.

✓ The sale of the particle analytical

equipment business (in FY2019

Q3) caused a drop in orders.

✓ Orders received declined due to

737 MAX production suspension.

✓ In hemodialysis business, dialysis

machine orders received fell slightly,

but the number of quotation

requests for domestic new

machines increased.

✓ Orders received for CRRT

(Continuous Renal Replacement

Therapy) business increased due to

higher needs for treatment of acute

kidney injury caused by COVID-19.


Revenue Analysis (vs FY2019)

< Medical>< Aerospace >< Industrial, etc. >

(Millions of JPY)

FY2019 Q1(Jan.2019-Mar.2019)

Revenue

37,480

△169＋1,366

Simpledecrease

△1,281

△410

△480

△24

Simpledecrease

Decreased 998 million yen year on year (Simple decrease: △395; Impact of FX: △603)

Impact of FX

Impact of FX

Impact of FXSimple

increaseFY2020 Q1

(Jan.2020-Mar.2020)Revenue

36,481

✓ In LEWA, shipments for existing

orders increased, but after-sales

service operations slowed down

due to COVID-19.

✓ The sale of the particle

analytical equipment business

(in FY2019 Q3) caused a drop in

revenue.

✓ Sales decreased due to 737 MAX

production suspension.

✓ Achieved strong hemodialysis

machine sales to China.

✓ Sales of disposables increased

in hemodialysis business.

✓ Strong sales of machines and

disposables in CRRT business.

Copyright © 2020 NIKKISO CO., LTD. All rights reserved.

< Medical>< Aerospace>< Industrial, etc. >

11

Operating profit Analysis (vs FY2019)

(Millions of JPY)

＋168 △70△148

FY2019(Jan.2019-Mar.2019)

Operating profit

2,154

△694△20

△109

△11

Decreased 886 million yen year on year (Simple decrease: △635; Impact of FX: △102;

Corporate expenses:△148)

Simpledecrease

Simpledecrease

Simpleincrease

Impact of FX

Impact of FX

Impact of FX Increase in corporate

expenses, etc. FY2020(Jan.2020-Mar.2020)

Operating profit

1,268✓ Shipments decreased in

Industrial Business.

✓ UV-LED licensing income

increased by 500 million yen.

✓ Sales of products used for

737 MAX declined.

✓ Depreciation and other

expenses of the Aerospace

factory in Miyazaki increased.

✓ CRRT business profitability

improved thanks to increased

sales.

✓ Production and logistics costs

increased in hemodialysis

business.

✓ Expenses related

to the

restructuring of

domestic bases

increased.


Industrial Division

FY2019 Q1Jan.2019 – Mar. 2019

FY2020 Q1Jan. 2020– Mar. 2020

YoY comparison

Change Change rate

Orders 21,676 20,251 △1,424 △6.6%

Revenue 17,536 17,227 △308 △1.8%

Revenue Composition ratio by Product

37%

7%14%8%

29%

5%

FY2020 Q1

Reciprocating pump

Canned motor pump

Cryogenics pump

Geveke

CI Group

Others

Topics

Q1 Results

Consolidated performance

(Millions of JPY)

• Crude oil prices fell in March due to fiercer price competition among oil-producing countries and the effects

of COVID-19. The suspension or postponement of ongoing projects is limited, but some new investment

deals have already been suspended or postponed.

• In industrial gas/LNG-related business, making decisions on some investment deals were postponed, and

there were some delays in the completion of deals.

• Continuously maintaining stable product supply through manufacturing bases around the world, while

ensuring employee safety as our top priority.

• Currently building a cryogenic pump testing facility in Miyazaki to meet the increasing demand for LNG from

a medium to long term perspective.


FY2020

13

Quarterly performance trend of LEWA

58

132

197

247

71

136

206

270

79

263

46

94

153

237

53

108

177

242

52

260

1 411

22

512

2634

5

33

106

133 138

95

115 123 125 124

151

-200

-150

-100

-50

0

50

100

150

0

50

100

150

200

250

300

350

Order (Left axis) Reveue (Left axis) EBITDA(Left axis) Order backlog(Right axis)

Q1 Q2 Q3 Q4 Q1 Q2 Q3

FY2018 FY2019

Q1 Q4Q3Q2Q4

2020(forecast)

(Millions of €)


Quarterly performance trend of CI group

54

87

137

212

51

96

140

180

42

230

31

65

112

124

43

87

113

182

46

209

1 511

175 9 11

163

20

114 108 111

138 146 147 150

136 136

-150

-100

-50

0

50

100

150

0

50

100

150

200

250

300

Order (Left axis) Reveue (Left axis) EBITDA(Left axis) Order backlog(Right axis)(Millions of ＄)

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

FY2018 FY20192020

(forecast)

Q1 Q4Q3Q2

FY2020


Precision Equipment Division

FY2019 Q1Jan.2019 – Mar. 2019

FY2020 Q1Jan. 2020– Mar. 2020

YoY comparison

Change Change rate

Orders 2,747 959 △1,788 △65.1%

Revenue 2,518 1,101 △1,417 △56.3%


Power plant-related equipment

Electronic component manufacturing equipment

Others

37%

48%

15%

FY2020Q1


Topics

Q1 Results

(Millions of JPY)

• Orders received for power plant-related equipment decreased year on year as we did not receive large

orders in foreign countries. Revenue increased as periodic inspections for thermal power plants were

intensively conducted.

• Orders for electronic component-related equipment have been pushed back to Q2 or later due to the

effects of COVID-19, although the MLCC market (a main market) is on track for recovery.

• No impact from COVID-19 on manufacturing as contract manufacturing continues.

*FY2019 Q1 figures include those related to the particle analytical equipment business (which was sold in FY2019 Q3).


Aerospace Division

FY2019 Q1Jan.2019 – Mar. 2019

FY2020 Q1Jan. 2020– Mar. 2020

YoY comparison

Change Change rate

Orders 4,102 3,734 △367 △9.0%

Revenue 4,168 3,664 △504 △12.1%


Cascade

Wing parts

Others

Jet engine parts

Nacelle parts36%

15%

29%

18%

2%

FY2020Q1


Topics

Q1 Results

(Millions of JPY)

• US-based Boeing’s suspension of 737 MAX production led to our suspension of cascade shipments for such

production, resulting in a decline in sales. Both revenue and profit decreased year on year due to increased

expenses, including depreciation expenses incurred at the Aerospace factory in Miyazaki.

• Demand for all types of aircrafts plunged suddenly as airline companies around the world significantly

decreased flights.

• Relocated equipment from Shizuoka to Miyazaki last year, and in March began to manufacture products

that used to be manufactured in Shizuoka. Currently carrying out transfer work, as scheduled, to start the

mass production of fan case liners in Miyazaki.


Medical Division

FY2019 Q1Jan.2019 – Mar. 2019

FY2020 Q1Jan. 2020– Mar. 2020

YoY comparison

Change Change rate

Orders 15,068 15,014 △53 △0.4%

Revenue 13,175 14,372 ＋1,197 ＋9.1%


10%

10%

32%

4%

12%

13%

19%

(Japan) Dialysis machines

(Overseas) Dialysis machines

(Japan) Disposable

Maintenance

CRRT

Others

FY2020Q1

Topics

Q1 Results


(Overseas) Disposable

(Millions of JPY)

• Sales of hemodialysis machine remained on par with the previous year, although sales activities were

restricted due to the effects of COVID-19. Hemodialysis business revenue rose as sales of disposables strong,

but profit fell due to increased manufacturing and logistics costs, etc.

• CRRT business and healthcare product sales grew due to higher needs for treatment of acute renal failure

and prevention of virus infections. CRRT business performance improved thanks to an increasing number of

quotation requests.

• Began building a new factory in Vietnam to enable the stable supply of blood tubing lines that have been

increasingly in demand around the globe.

• Decided to build a medical training center in Miyazaki as part of the restructuring of bases (scheduled to be

established in May 2021). Aim to further strengthen relationships with medical personnel by providing them

with valuable experiences.

Ⅲ. Financial forecast


Consolidated Performance

(Millions of JPY）

FY2019

Actual record

FY2020

Performance forecastYoY comparison

Change Change rate

Orders 167,034 177,000 +9,965 +6.0%

Revenue 165,780 174,000 +8,219 +5.0%

Operating profit 12,466 11,000 △1,466 △11.8%

Operating margin 7.5% 6.3%

Profit before tax 11,381 10,000 △1,381 △12.1%

Pretax profit margin 6.9% 5.7%

attributable to owners of the company

Profit for the year 6,813 6,000 △813 △11.9%

Profit margin attributable to owners of the company

4.1% 3.4%

Average/ForecastAgainst the US dollar (Yen)

Against the euro (Yen) 109.03122.03

109.00120.00

△0.03△2.03

Forex sensitivity for FY2020 (When

yen was depreciated by 1 yen)

US dollar (Yen)

Euro (Yen)

Revenue +460 million yen Operating profit +80 million yenRevenue +400 million yen Operating profit +70 million yen

Financial forecast remains unchanged. After assessing the impact of environmental changes in each business, strengthening

various measures and analyzing the effects of countermeasures in detail, if any revision becomes necessary in future, the

Company will disclose new forecast immediately.


Performance by Business Segment

（Millions of JPY）

FY2019Actual record

FY2020

Performance forecastYoY comparison

Orders 167,034 177,000 +9,965 +6.0%

Industrial Business 104,437 111,000 +6,562 +6.3%

Industrial 77,623 85,000 +7,376 +9.5%

Precision Equipment 7,571 6,500 △1,071 △14.2%

Aerospace 17,926 18,500 +573 +3.2%


Revenue 165,780 174,000 +8,219 +5.0%

Industrial Business 103,734 108,000 +4,265 +4.1%

Industrial 75,238 82,000 +6,761 +9.0%

Precision Equipment 9,233 6,500 △2,733 △29.6%

Aerospace 17,955 18,500 +544 +3.0%


Operating ProfitOperating margin

12,4667.5%

11,0006.3%

△1,466 △11.8%

Industrial BusinessOperating margin

10,85110.5%

10,2009.4%

△651 △6.0%

Medical BusinessOperating margin

3,4475.6%

5,5008.3%

+2,052 +59.5%

Corporate Expenses △1,833 △4,700 △2,866

Appendix


34,492

75,578

115,437

165,326

37,480

78,956

121,193

165,780

36,481

84,000

174,000

864

3,168

6,308

10,302

2,154

3,558

9,511

12,466

1,268

4,000

11,000

0

2,500

5,000

7,500

10,000

12,500

15,000

17,500

20,000

0

30,000

60,000

90,000

120,000

150,000

180,000

Revenue Operating Profit

FY2018

Q1 Q2 Q3 Q4

Quarterly results trend

（Millions of JPY）

FY2019 FY2020


1$ = 110.44Yen1€ = 130.35Yen


1$ = 109.03Yen1€ = 122.03Yen

Foreign exchange rate (forecast)

1$ = 109.00Yen1€ = 120.00Yen


Consolidated Statement of Financial Position

As of end of December 2019 As of end of March 2020

(Millions of JPY）Amount

Composition ratio Amount

Composition ratio Change

Total assets 252,984 100.0% 261,543 100.0% ＋8,558

Total current assets 113,020 44.7% 120,139 45.9% ＋7,118

Cash and cash equivalents 20,303 8.0% 27,912 10.7% ＋7,608

Trade and other receivables 53,256 21.1% 49,194 18.8% △4,062

Inventories 35,523 14.0% 38,563 14.7% ＋3,039

Total non-current assets 139,964 55.3% 141,403 54.1% ＋1,439

Property, plant and equipment 41,849 16.5% 43,836 16.8% ＋1,986

Goodwill and Intangible assets 61,105 24.2% 61,263 23.4% ＋158

Total liabilities 169,571 67.0% 181,600 69.4% ＋12,028

Trade and other payables 28,231 11.2% 26,446 10.1% △1,785

Bonds and borrowings 104,731 41.4% 117,331 44.9% ＋12,599

Total equity 83,413 33.0% 79,942 30.6% △3,470


Revenue Composition Ratio by Region

81%

19%Japan

Asia

North America

Europe

Others

21%

5%

70%

4%

66%

19%

12%

2%

20%

30%

40%

50%

60%

70%

0

20,000

40,000

60,000

80,000

100,000

120,000

09/3 10/3 11/3 12/3 13/3 14/3 15/3 15/12 16/12 17/12 18/12 19/12

Asia North America

Europe Others

Overseas revenue ratio (right axis)

Overseasrevenue ratio

63%

(9 months)

（Millions of JPY)

13%

36%

23%

24%

3%

FY2020Q1

Japan

37%

Asia25%

North America

18%

Europe17%

Others2%

FY2020Q1

FY2020Q1

FY2020Q1

FY2020Q1

Industrial Precision Equipment Aerospace Medical

Nikkiso Group Total Revenue trend by overseas region


Breakdown of forex sensitivity

（Millions of JPY）FY2020

Performance forecast

Against the US dollar Against the euro

RevenueOperating

profitRevenue

Operating

profit

Industrial Division/

Precision Equipment Division+310 +20 +320 +30

Aerospace Division +140 +90 +0 +0

Medical Division +10 △30 +80 +40

Total +460 +80 +400 +70

Average/Forecast (Yen） 109.00 120.00

※When yen was depreciated by 1 yen


Financial data

FY2016 FY2017 FY2018 FY2019

Earnings per share (Basic) 66.08yen 72.82yen 104.63yen 95.68yen

Return on equity (ROE) 7.2% 7.3% 9.8% 8.6%

Return on asset (ROA) 3.8% 3.9% 3.9% 4.5%

Operating margin 6.2% 6.2% 6.2% 7.5%

Equity ratio 37.4% 30.7% 30.7% 32.2%

Debt/equity ratio 1.05times 1.63times 1.53times 1.28times

(Millions of JPY) FY2016 FY2017 FY2018 FY2019

Capital expenditure 7,635 7,508 12,869 7,220

Research and development expenditure 1,679 2,435 2,387 2,346

Depreciation and amortization 4,766 5,246 6,335 8,994


(Millions of JPY） 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter

FY201820,066 19,760 18,808 23,604

overseas 18,316 17,659 16,974 20,488

FY201921,676 19,727 18,147 18,075

overseas 20,422 16,050 16,819 15,704

FY202020,251

overseas 18,241

（Millions of JPY） 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter

FY201843,058 44,457 43,496 43,674

overseas 40,088 41,298 40,305 39,608

FY201947,813 49,402 48,938 46,058

overseas 44,435 44,282 44,900 41,700

FY202049,883

overseas 45,730

Orders

Order Backlog

Quarterly orders/order backlog trend of Industrial Division


Quarterly revenue trend

（Millions of JPY） 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter

Industrial

FY201815,206 18,361 19,770 23,426

overseas 13,247 16,289 17,809 21,203

FY201917,536 18,138 18,610 20,953

overseas 15,595 16,203 16,567 18,535

FY202017,227

overseas 15,012

Precision Equipment

FY20182,516 2,640 2,187 3,339

overseas 604 794 739 1,177

FY20192,518 2,947 1,589 2,177

overseas 896 1,113 662 1,394

FY20201,101

overseas 210

Aerospace

FY20183,792 4,213 3,924 4,980

overseas 3,301 3,648 3,114 4,240

FY20194,168 4,431 4,656 4,698

overseas 3,389 3,704 3,803 3,874

FY20203,664

overseas 2,892

Medical

FY201812,936 15,855 13,943 18,090

overseas 4,148 4,586 4,682 5,335

FY201913,175 15,861 16,681 16,327

overseas 4,193 4,703 4,420 5,255

FY202014,372

overseas 4,849

Company Information


Consolidated Revenue

Industrial business 63%

Medical business37%

Industrial

45%Medical

37%

Aerospace

11%

FY2019

Precision Equipment

6%0

5,000

10,000

15,000

20,000

25,000

30,000

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

180,000

FY2009 FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019

国内売上海外売上営業利益(billion yen)

165.7165.3

140.9

130.0

110.2

129.2

121.5

103.6

90.183.1

78.012.110.3

8.78.1

3.86.1

9.47.46.5

5.35.6

10/3 11/3 12/3 13/3 14/3 15/3 15/12 16/12 17/12 18/12 19/12

JGAPP IFRS

11-Year Summary Revenue by segment

Operating

Profit

Domestic

revenue

Overseas

revenue


Performance trend of Industrial Business

33,663 43,076

52,393 54,663

69,307

79,239

69,536 75,183

85,406

111,459

103,927

111,000

37,233

42,123

47,490

55,176

68,588

74,960

68,625

75,593

85,228

104,501 103,734 108,000

3,444 2,760 4,662 3,770 5,102 4,375 3,668

5,932 7,539 8,140 10,851 10,200

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

20.0%

0

20,000

40,000

60,000

80,000

100,000

120,000

2010/03 2011/03 2012/03 2013/03 2014/03 2015/03 2015/12 2016/12 2017/12 2018/12 2019/12 2020/12

Orders Revenue

Operating profit (Left axis) Operating margin (Right axis)

(IFRS)(IFRS)(IFRS)(9months) (forecast)(IFRS)

Acquired the LEWA Group

Acquired Geveke B.V.

Acquired the Cryogenic Industries group

Miyazaki Nikkiso Aerospace factory

Higashimurayama Aerospace factory

Aerospace product expansion

Transferred production from Shizuoka to Kanazawa

(Millions of JPY)


Performance trend of LEWA

（Millions of €）

132

195 194204

220236 232

200

247270

129148

189

217 217 224 219236 237 242

13 1727 30 31 28 21 28 22

34

0

20

40

60

80

100

120

0

50

100

150

200

250

300

10 11 12 13 14 15 16 17 18 19

Order (Left axis) Revenue (Left axis) EBITDA (Left axis) Crude oil price (Right axis)

（＄/barrel）

（Source）Crude oil price：The World Bank Group「Commodity Markets Outlook」

36%

41%

23%Oil&Gas

Process industry

Clean market

After service

Revenue Composition ratio

FY2010

34%

36%

6%

24%

FY2015

25%

38%

10%

28%

FY2019


Performance trend of Medical Business

(IFRS)(IFRS)(IFRS)

40,786 41,019 42,646

48,493 52,960

54,295

41,592

54,451 55,684

60,824 62,046

66,000

5,226 5,598 5,224 6,962 7,845

5,243 3,041

5,209 3,950 5,582

3,447 5,500

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

20.0%

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

2010/03 2011/03 2012/03 2013/03 2014/03 2015/03 2015/12 2016/12 2017/12 2018/12 2019/12 2020/12

Revenue Operating profit (Left axis) Operating margin (Right axis)

(IFRS)

(Millions of JPY)

Full-scale sales of DCS-100NX, a multipurpose dialysis monitoring device (from January 2012)

Sales of DBB-EXA, a dialysis device for personal use (in overseas markets) (from 2015)

Higher demand for online HDF

Consumption tax hike in April 2014 (to 8% from 5%)

Acquired the CRRT business

Transferred production from Shizuoka to Kanazawa

Full-scale sales of DCS-200Si, a multipurpose dialysis monitoring device (from July 2019)

(9months) (forecast)


History

69 71 74 75 83 87 95 01 09 1053 54 56 60 61 67 13 15 1714 1808 19

Industrial Division

Medical Division

Aerospace Division

Company is established for the purpose of import and sales of reciprocating metering pumps.

Develops a water conditioning system for power plants and begins production and sales of systems.

Introduces Japan’s first leak-free canned motor pump technology and begins production and sales of pumps.

Begins import and sales of artificial dialysis machines for the first time in Japan.

Completes Japan’s first hemodialysis machine and begins production and sales of machines.

Begins production and sales of dialyzers for hemodialysis.

Begins production and sales of cascades made of carbon fiber reinforced plastic as components for commercial aircraft.

Begins manufacturing and sales of cryogenic pumps.

Begins production of bloodtubing lines for hemodialysisin Vietnam.

Establishes the Deep UV-LED Business Joint-Venture Company with Formosa Plastic Group.

Completes construction of HigashimurayamaPlant.

Listing on the second section of the Tokyo Stock Exchange.

Listing on the first section of the Tokyo Stock Exchange.

Completes construction of Shizuoka Plant.

Completes construction ofKanazawa Plant.

Acquires the LEWA Group of Germany.

Establishes a joint venture with the China-based Weigao for the manufacture and maintenance of dialysis machine

Acquires Geveke B.V. of the Netherland

Acquires CRRT business of Baxter International Inc.

Acquires Cryogenic pump business of Atlas Copco.

Acquires the Cryogenic Industries Group of U.S.A.

Completes construction ofAerospace factory at theMiyazaki Nikkiso, and Vietnam No.2 factory.

Establishes a Nikkiso Vietnam,Inc.

Documents

Financial results for FY2020 Q1 Financial Summary · 2020-05-20 · Financial results for FY2020 Q1 Financial Summary NIKKISO CO., LTD. May 15, 2020 Securities code: 6376 Disclaimer